Despite many medication-and device-based improvements that have become guideline-based therapy, there is still a compelling clinical need to enhance cardiac function and outcomes in HF patients (4, 5) .
Recombinant neuregulin (NRG)-1b is a naturally occurring growth factor that acts directly on cardiomyocytes and is being explored as a potential therapy for HF. NRG-1b regulates cardiac development through receptor tyrosine kinases in the epidermal growth factor receptor family, ERBB2-4 (6).
The importance of this NRG-1/ERBB signaling pathway in the adult heart was demonstrated clinically when unexpectedly high rates of cardiotoxicity were observed in association with the chemotherapeutic agent trastuzumab, a monoclonal antibody that blocks the ERBB2 receptor (7, 8) . These clinical results and the ability of NRG-1b to activate cytoprotective mechanisms in cardiac myocytes has prompted investigations of its potential to enhance cardiac function in HF (9, 10) . Recent animal data support this notion. NRG-1b is released in response to ischemia, stress, and exercise, and is beneficial in animal models of cardiac injury by promoting restorative remodeling (11) (12) (13) . A recombinant peptide representing the epidermal growth factor-like domain of NRG-1b (Neucardin, Zensun USA Inc., San Diego, California) has been studied in humans with stable chronic HF, where it improved hemodynamics acutely (14) and when given by prolonged infusion over many days increased left ventricular (LV) systolic function (15) .
A larger full-length recombinant NRG-1b3 known as cimaglermin alfa (cimaglermin; also known as NRG1b3, glial growth factor [GGF]-2) is also being examined as a possible treatment for HF (12, 13) . Although cimaglermin and Neucardin both act on ERBB receptor tyrosine kinases, the larger cimaglermin is distinct in structure, containing kringle and immunoglobulinlike domains (16, 17) , and is manufactured in a mammalian cell expression system leading to complex glycosylation. The other domains of cimaglermin, beyond the epidermal growth factor-like domain, provide additional differences from the fragment including receptor binding, signaling, recycling, and extracellular matrix binding (18) (19) (20) (21) (22) . Cimaglermin improves cardiac function in rats and swine after myocardial infarction, even when administered as brief intravenous infusions twice per week (11) (12) (13) . In addition to the HF models, cimaglermin has been shown to protect cardiomyocytes from toxicity both in vitro (23, 24) and in vivo (25) .
Given the preclinical promise of cimaglermin, we conducted a first-in-human, phase 1, randomized, Association functional class
Phase I Study of Cimaglermin in LVSD and HF were maintained on an optimal medical regimen for at least 3 months before enrollment at Vanderbilt University Medical Center or Emory Heart and Vascular Center at Emory Saint Joseph's. All patients had an LVEF #40% on screening, no significant renal or liver disease, and an existing implantable cardioverter-defibrillator. Given the theoretical risk of administering a growth factor, patients with a history of cancer were excluded and an age- DLT is defined as 1 of the following events deemed to be at least possibly related to study drug: 1) grade III toxicity or above (would encompass life-threatening events); 2) liver function abnormalities as defined in protocol; or 3) other events clinically judged to necessitate dose reductions. If a DLT occurs in the dose reduction step, the decision on whether to stop the study or to continue (reducing the dose by 1 additional dose level) will be made by sponsor and the principal investigator in consultation with the DSMB. DLT ¼ dose-limiting toxicity; DSMB ¼ Data Safety Monitoring Board; GGF ¼ glial growth factor; PBO ¼ placebo. PK ¼ pharmacokinetics.
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RESULTS
Forty patients of a planned 42 (7 cohorts of 6 patients) were enrolled as study recruitment was suspended following a serious adverse event (SAE) in the 40th patient. Eighty-three percent (n ¼ 33) of patients enrolled were male, 60% had NYHA functional class II, and 40% had NYHA functional class III symptoms. Values are mean AE SD or n (%).
HF ¼ heart failure; LVEF ¼ left ventricular ejection fraction; NYHA ¼ New York Heart Association. Values are n (%). Patients previously on strong CYP3A/4 inhibitors had dose adjustments 2 weeks prior to receiving study drug, as cimaglermin was observed to affect CYP3A4 activity in vitro, which is being explored clinically.
ACEI ¼ angiotensin-converting enzyme inhibitor; ARB ¼ angiotensin receptor blocker; MRA ¼ mineralocorticoid receptor antagonist.
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Seventy-three percent (n ¼ 29) had known significant coronary disease and established ischemic HF. The mean age was 57.4 AE 9.8 years. Other patient characteristics and concomitant medications during the study period are shown in Tables 1 and 2 . Patients were maintained on optimal medical therapy for at least 3 months before enrollment in the trial ( Table 2) .
Given the small size of the study, the demographics were relatively well matched. There were no clinically significant treatment effects of a single dose of cimaglermin on hematologic, electrical, or the majority of biochemical safety laboratory testing performed, with the exception of the DLT described in more detail below.
There were no acute AEs leading to termination of drug infusion. There were no study withdrawals due to AEs. The most frequently observed treatmentemergent adverse events (TEAEs) are shown in Table 3 . A TEAE was defined as an event with a date of onset, or worsening, on or after the start of double- Table 4 , and the primary exploratory efficacy measure of LVEF is displayed in Figure 3 with additional data provided in the Supplemental Figure. There was a sustained, doserelated increase in LVEF through 90 days after dosing in the high-dose cimaglermin group when compared with the placebo group, (p < 0.01) (Figures 3 and 4B) . There was no change in LVEF in Congestive heart failure 0 0 1 (7) Hy's law case 0 0 1 (7)
Values are n (%). *Common Terminology Criteria for Adverse Events grade 3 or higher.
BNP ¼ B-type natriuretic peptide; GGT ¼ gamma-glutamyl transferase; TEAE ¼ treatmentemergent adverse event.
placebo-treated patients. In low-dose cimaglermin treated patients, there was a small nonsignificant increase in LVEF which returned to baseline by 90 days.
In the high-dose cimaglermin treated patients, there was a mean increase of 9 absolute percentage units of LVEF, and changes reached their maximum increase at day 28 ( Figure 3) and were sustained throughout the duration of the safety measurements. Additionally, at the 90-day time point there was a nonsignificant trend toward a reduction in LVESV, especially at the higher doses (-23.2 ml compared with baseline).
The AUC for absolute changes in LVEF during the 90 days of observation by dose groups is shown in Figures 4A and 4B ; the high-dose group (0.189-mg/kg, 
DISCUSSION
In this first-in-human study of cimaglermin, a dose range for future studies was identified. There were no discontinuations based on AEs. Overall, the most commonly experienced TEAEs were nausea (7 of 27, 26%) and headache (9 of 27, 33%) that were temporally associated with study drug exposure.
Nausea occurred in some patients who received a placebo infusion (2 of 13, 15%). A DLT of transient liver transaminase elevation and hyperbilirubinemia was observed in 1 patient at the highest planned dose.
Some liver enzyme changes were anticipated at higher doses based on preclinical toxicology studies.
The liver transaminase elevation and hyperbilirubinemia observed, although it met criteria for Hy's law, was temporary and not associated with any long-term sequelae for the subject.
In addition to these safety findings, the results of the study appear to indicate that a single infusion of At 90 days, only the highest dose group showed a significant increase compared with the placebo group (p < 0.01).
Abbreviations as in Figures 1 and 2 . STUDY LIMITATIONS. The limitations of this study, by the nature of the design, is that it is a small study intended to document safety. Because it was a first-in-man dose-escalating study, the initial doses in humans were known to be subtherapeutic in animal studies. Similarly, there was only a single infusion as opposed to multiple doses for the same reason to maximize patient safety. Lastly, the relatively short time for follow-up is sufficient to detect potential changes in cardiodynamics but not long enough to establish a difference in major clinical events.
CONCLUSIONS
A single intravenous dose of cimaglermin was tolerated in the majority of patients with systolic LV dysfunction and HF in a first-in-human safety study. The most common AEs, occurring more frequently at the higher doses, were headache (33%)
followed by nausea (27%). Serious TEAEs were uncommon, and the DLT at the highest planned dose 
